October 9, 2025
Headlines

Biotech

Foray Bioscience Secures $3 Million to Revolutionize Biomanufacturing for Ecosystem Conservation

Editor06 mins

Foray Bioscience, a pioneering force in sustainable biotechnology, has announced a significant milestone with the successful closure of a $3 million seed funding round led by ReGen Ventures. This latest injection of capital, supported by prominent investors including The Engine Ventures and Susquehanna Sustainable Investments, underscores Foray’s commitment to reshaping the future of plant-based industries…

Read More

EpilepsyGTx Secures $10M to Advance Breakthrough Gene Therapy for Focal Refractory Epilepsy

Editor05 mins

EpilepsyGTx, a pioneering biotechnology firm specializing in advanced gene therapies for focal refractory epilepsy, has announced a successful $10 million seed funding round. The financing, spearheaded by the UCL Technology Fund and bolstered by Health Technology Holding, marks a significant milestone in the company’s journey towards combating this challenging neurological disorder. Led by CEO Nicolas…

Read More

Vico Therapeutics Secures €65.8 Million in Series B Funding to Advance Groundbreaking Neurological Therapies

Editor04 mins

Vico Therapeutics, a pioneering clinical-stage genetic medicines company, has successfully closed its Series B funding round with a total investment of €65.8 million ($70.7 million). This financing round, led by Seroba and Kurma Partners, marks a significant milestone in Vico’s journey towards developing transformative therapies for severe neurological diseases. Vico Therapeutics specializes in antisense oligonucleotide…

Read More

Valneva’s Breakthrough: Canada Approves World’s First Chikungunya Vaccine

Editor02 mins

Valneva SE has achieved a historic milestone with Health Canada’s approval of the world’s first chikungunya vaccine. Following its successful launch in the U.S. and pending European authorization, this decision underscores IXCHIQ®’s pivotal role in global healthcare strategy. Chikungunya, a mosquito-borne virus causing severe joint pain and fever, poses a significant public health threat with…

Read More

Ethris GmbH: Leading the Charge in mRNA-Based Therapeutics with $5 Million Investment

Editor04 mins

Since its inception, Ethris GmbH has been a trailblazer in mRNA technology, revolutionizing the biotech landscape with its innovative approach to respiratory and cardiovascular diseases. Founded on a vision of harnessing messenger RNA (mRNA) for therapeutic breakthroughs, Ethris has consistently pushed boundaries, drawing attention from investors and global biotech leaders alike. Breakthroughs and Strategic Growth…

Read More